AssetMark Inc
SRPT icon

AssetMark Inc’s Sarepta Therapeutics SRPT Stock Holding History

AssetMark Inc’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Sell
672
-49
-7% -$927 ﹤0.01% 2382
2026
Q1 		$15.7K Sell
721
-30
-4% -$581 ﹤0.01% 2145
2025
Q4 		$16.2K Sell
751
-57
-7% -$1.2K ﹤0.01% 2060
2025
Q3 		$15.6K Sell
808
-11,865
-94% -$212K ﹤0.01% 1992
2025
Q2 		$217K Buy
12,673
+220
+2% +$9.39K ﹤0.01% 1201
2025
Q1 		$795K Sell
12,453
-30,306
-71% -$3.19M ﹤0.01% 906
2024
Q4 		$5.2M Buy
42,759
+3,734
+10% +$458K 0.01% 492
2024
Q3 		$4.87M Buy
39,025
+27,220
+231% +$3.76M 0.01% 455
2024
Q2 		$1.87M Buy
11,805
+3,338
+39% +$429K 0.01% 633
2024
Q1 		$1.1M Buy
8,467
+1,800
+27% +$220K ﹤0.01% 712
2023
Q4 		$643K Buy
6,667
+2,851
+75% +$273K ﹤0.01% 756
2023
Q3 		$463K Buy
3,816
+558
+17% +$63.1K ﹤0.01% 769
2023
Q2 		$373K Buy
+3,258
New +$420K ﹤0.01% 769

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AssetMark Inc's SRPT Position: Q2 2026 in Review

AssetMark Inc reduced its Sarepta Therapeutics (SRPT) stake by 6.8% in Q2 2026, selling an estimated $927 and leaving 672 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

AssetMark Inc first reported a position in SRPT in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.2M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • AssetMark Inc held 672 shares of Sarepta Therapeutics worth $12.1K as of Q2 2026.
  • AssetMark Inc sold 49 Sarepta Therapeutics shares in Q2 2026, an estimated $927.
  • Sarepta Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2382 holding.
  • AssetMark Inc first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • AssetMark Inc's Sarepta Therapeutics position peaked at $5.2M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.